サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1644234

ラジオセラノスティクスの世界市場

Radiotheranostics

出版日
ページ情報
英文 168 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ラジオセラノスティクスの世界市場
出版日: 2025年01月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 168 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ラジオセラノスティクスの世界市場は2030年までに224億米ドルに達する見込み

2024年に104億米ドルと推定されるラジオセラノスティクスの世界市場は、分析期間2024-2030年にCAGR 13.6%で成長し、2030年には224億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的診断モダリティは、CAGR 7.5%を記録し、分析期間終了までに98億米ドルに達すると予測されます。標的治療薬セグメントの成長率は、分析期間中CAGR 20.5%と推定されます。

米国市場は27億米ドルと推定、中国はCAGR13.0％で成長予測

米国のラジオセラノスティクス市場は、2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに35億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.7%と12.1%と予測されています。欧州では、ドイツがCAGR 10.4%で成長すると予測されています。

世界のラジオセラノスティクス市場- 主要動向と促進要因のまとめ

ラジオセラノスティクスをプレシジョン医療の最前線に押し上げる要因とは？

画像診断と標的放射線治療を組み合わせた最先端のアプローチであるラジオセラノスティクスは、個別化医療のゲームチェンジャーとして台頭しています。この二重機能技術により、腫瘍の正確な同定と、放射性医薬品を用いたオーダーメイド治療が可能になり、健康な組織へのダメージを最小限に抑えることができます。がんの罹患率が世界的に上昇を続ける中、ラジオセラノスティクスは、より効果的で侵襲の少ない治療法を提供できるとして支持を集めています。さらに、ラジオセラノスティクスの核医学への統合は、腫瘍学に革命をもたらし、患者により良い転帰と生活の質を提供します。精密医療へのシフトが進む中、ラジオセラノスティクスはがんとの闘いにおいて極めて重要なツールとなっています。

技術革新はラジオセラノスティクスの範囲をどのように再定義しているのでしょうか？

技術の進歩は、ラジオセラノスティクスの能力を拡大する上で中心的な役割を果たしています。ルテチウム-177やアクチニウム-225のような放射性同位元素のような新しい放射性医薬品の開発は、画像診断と治療の両方においてより高い精度を可能にしています。PET/CTやSPECT/CTなどの分子イメージング技術の進歩は、病気の診断や治療モニタリングの精度を向上させています。さらに、人工知能と機械学習が放射線治療ワークフローに組み込まれ、画像解釈を強化し、治療計画を最適化しています。このような技術革新は、臨床的な成功を促進するだけでなく、製薬会社や研究機関がラジオセラノスティクス開発に多額の投資を行うことを後押ししています。

ラジオセラノスティクスの新たなアプリケーションと動向は？

ラジオセラノスティクスの応用は、前立腺がんや神経内分泌腫瘍の治療で顕著な成功を収めた腫瘍学以外にも急速に拡大しています。研究者は、特定の生物学的経路を標的とする能力を活用することで、心血管系疾患や特定の感染症など、他の疾患への対処の可能性を探っています。新たな動向として、免疫療法や化学療法と組み合わせて治療効果を高める併用療法があります。さらに、放射性医薬品の生産とサプライチェーン・ロジスティクスの進歩は、スケーラビリティの課題に対処し、これらの治療法が多様なヘルスケア環境においてより広く患者に提供されることを保証しています。

ラジオセラノスティクス市場の急成長の原動力は？

ラジオセラノスティクス市場の成長は、いくつかの要因によってもたらされています。世界のがん罹患率の増加により、革新的な治療法に対するニーズが高まっており、ラジオセラノスティクスは重要な注目分野となっています。放射性医薬品開発と分子イメージング技術の大幅な進歩により、これらの治療法の有効性とアクセシビリティが向上しています。核医学インフラへの投資の増加や新興国市場におけるヘルスケア予算の拡大も市場成長を加速させています。さらに、患者やヘルスケアプロバイダーの間で個別化された治療アプローチを好む傾向が強まっていることも、ラジオセラノスティクスの採用を後押ししています。規制当局の支援と有利な償還政策は、この有望な技術の普及にさらに貢献し、精密医療の将来におけるその役割を確固たるものにしています。

セグメント

モダリティ（標的診断薬、標的治療薬）;ラジオアイソトープ（ルテチウム-177ラジオアイソトープ、ガリウム-68ラジオアイソトープ、ヨウ素-131ラジオアイソトープ、ヨウ素-123ラジオアイソトープ、その他のラジオアイソトープ）;アプリケーション（オンコロジーアプリケーション、非オンコロジーアプリケーション）

調査対象企業の例（注目の36社）

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32753

Global Radiotheranostics Market to Reach US$22.4 Billion by 2030

The global market for Radiotheranostics estimated at US$10.4 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Targeted Diagnostics Modality, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Targeted Therapeutics Modality segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.0% CAGR

The Radiotheranostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Radiotheranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Radiotheranostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Focus on Precision Medicine and Targeted Therapies Drives Market Growth
    • Rising Adoption of Theranostic Agents in Oncology Treatments Propels Industry Expansion
    • Growing Use of PET Imaging in Radiotheranostic Applications Fuels Demand
    • Expansion of Nuclear Medicine Facilities Supporting Radiotheranostics Enhances Market Potential
    • Advancements in Radiolabeling Technologies for Improved Accuracy Propel Technological Growth
    • Integration of AI Tools in Radiotheranostic Imaging and Diagnostics Drives Innovation
    • Increasing Demand for Personalized Treatment Protocols in Cancer Care Boosts Adoption Rates
    • Collaboration Between Pharmaceutical and Diagnostic Companies in Radiotheranostics Drives Market Expansion
    • Role of Radiotheranostics in Emerging Immuno-Oncology Treatments Fuels New Opportunities
    • Rising Utilization of Theranostics for Non-Oncological Conditions Enhances Market Demand
    • Growing Interest in Dual-Modality Imaging Techniques Drives Technological Advancements
    • Investments in R&D for Novel Radiotheranostic Compounds Propel Industry Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Radiotheranostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Targeted Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lutetium-177 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Lutetium-177 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gallium-68 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Gallium-68 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Iodine-131 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Iodine-131 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Iodine-123 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Non-Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • JAPAN
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CHINA
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • EUROPE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • FRANCE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • GERMANY
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030

IV. COMPETITION